In a 73-year-old man with benign prostatic hyperplasia not on any prostate medication and a serum PSA of 5.5 ng/mL, what is the appropriate next step in evaluation and management?

Perform Digital Rectal Examination and Consider Prostate Biopsy

This 73-year-old man with BPH and PSA 5.5 ng/mL requires a digital rectal examination (DRE) immediately, and if abnormal, should proceed directly to prostate biopsy; if DRE is normal, he should still undergo prostate biopsy given his PSA exceeds the traditional 4.0 ng/mL threshold for cancer evaluation. 1

Rationale for Biopsy Recommendation

The PSA of 5.5 ng/mL significantly exceeds the established 4.0 ng/mL threshold that has been the standard indication for prostate biopsy since the 1980s 1. While this patient carries a diagnosis of BPH, elevated PSA levels correlate directly with prostate cancer risk, and 30-35% of men with PSA in the 4-10 ng/mL range will have cancer on biopsy 2, 3.

Key Clinical Considerations:

• PSA cannot distinguish between BPH and cancer in this range—there is significant overlap between benign and malignant conditions 2
• At age 73, if this patient has at least 10 years life expectancy, early cancer detection could significantly impact mortality and quality of life 4, 5
• The fact he is not on any prostate medications means this PSA value is not artificially suppressed by 5-alpha reductase inhibitors (which reduce PSA by approximately 50%) 3

Immediate Evaluation Steps

1. Digital Rectal Examination

Perform DRE to assess for:

• Nodules or areas of induration
• Asymmetry or increased firmness
• Overall prostate consistency

If DRE reveals any abnormality (nodule, asymmetry, firmness), proceed immediately to biopsy 1

2. Confirm PSA Elevation

Before biopsy, confirm the PSA under standardized conditions 5:

• No ejaculation for several days prior
• No recent prostate manipulation
• Rule out active urinary tract infection
• Repeat in same laboratory

3. Consider Pre-Biopsy MRI

Multiparametric MRI should be strongly considered before biopsy 5. The 2024 EAU guidelines demonstrate that MRI-based biopsy strategies:

• Reduce unnecessary biopsies
• Detect fewer clinically insignificant cancers
• Identify more clinically significant cancers (sensitivity 0.95 for ISUP grade ≥3) 5

If MRI shows PI-RADS 4-5 lesions, targeted biopsy of these areas plus systematic sampling is indicated 5.

Biopsy Protocol

When proceeding to biopsy 6, 5:

• Systematic transrectal ultrasound-guided biopsies (minimum 10-12 cores from peripheral zone)
• MRI-targeted biopsies if suspicious lesions identified
• Local anesthesia to minimize discomfort 3
• Antibiotic prophylaxis against gram-negative bacteria 6

Common Pitfalls to Avoid

1. Do not assume elevated PSA is solely from BPH - Even with known BPH, cancer must be ruled out at this PSA level
2. Do not delay evaluation based on age alone - At 73, many men have >10 years life expectancy and would benefit from curative treatment if cancer is detected 4, 3
3. Do not use PSA velocity alone without addressing the absolute PSA value - The baseline PSA of 5.5 ng/mL already warrants investigation 2

If Biopsy is Negative

Should initial biopsies be negative with persistent elevated PSA 6, 3:

• Repeat PSA in 3-6 months
• Consider additional biomarkers (percent free PSA, 4Kscore, phi) 3
• Multiparametric MRI if not already performed
• Repeat biopsy if PSA remains elevated or rises further

Management of BPH Concurrent with Evaluation

While cancer evaluation proceeds, BPH symptoms can be addressed 7:

• Alpha-blockers for symptom relief (first-line for LUTS)
• 5-alpha reductase inhibitors are appropriate given likely prostatic enlargement, but note these will reduce PSA by ~50% and complicate future cancer monitoring 7
• Consider deferring 5-ARI initiation until after cancer evaluation is complete

The priority here is cancer exclusion given the PSA elevation—BPH treatment optimization is secondary until malignancy is ruled out.